These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 22736481)

  • 1. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
    Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
    Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
    Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
    Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
    Nasca V; Prinzi N; Coppa J; Prisciandaro M; Oldani S; Ghelardi F; Conca E; Capone I; Busico A; Perrone F; Tamborini E; Sabella G; Greco G; Greco FG; Tafuto S; Procopio G; Morano F; Niger M; Maccauro M; Milione M; de Braud F; Pietrantonio F; Pusceddu S
    Eur J Cancer; 2024 Sep; 209():114276. PubMed ID: 39128186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
    Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
    Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
    Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
    Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
    Hescot S; Leboulleux S; Amar L; Vezzosi D; Borget I; Bournaud-Salinas C; de la Fouchardiere C; Libé R; Do Cao C; Niccoli P; Tabarin A; Raingeard I; Chougnet C; Giraud S; Gimenez-Roqueplo AP; Young J; Borson-Chazot F; Bertherat J; Wemeau JL; Bertagna X; Plouin PF; Schlumberger M; Baudin E;
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4006-12. PubMed ID: 23884775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
    Jasim S; Suman VJ; Jimenez C; Harris P; Sideras K; Burton JK; Worden FP; Auchus RJ; Bible KC
    Endocrine; 2017 Aug; 57(2):220-225. PubMed ID: 28685225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
    Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
    Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.